IBRX Key Statistics, Chart & Performance
The current stock price of IBRX is 2.04 USD. In the past month the price decreased by -13.56%. In the past year, price decreased by -27.4%.
IBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About IBRX
Company Profile
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 673 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Company Info
IMMUNITYBIO INC
3530 John Hopkins Court
San Diego CALIFORNIA 92121 US
CEO: Richard Adcock
Employees: 673
Phone: 18446965235
IMMUNITYBIO INC / IBRX FAQ
Can you describe the business of IMMUNITYBIO INC?
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 673 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
What is the current price of IBRX stock?
The current stock price of IBRX is 2.04 USD. The price decreased by -4.67% in the last trading session.
Does IBRX stock pay dividends?
IBRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IBRX stock?
IBRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for IBRX stock?
11 analysts have analysed IBRX and the average price target is 10.61 USD. This implies a price increase of 420% is expected in the next year compared to the current price of 2.04.
What is the Price/Earnings (PE) ratio of IMMUNITYBIO INC (IBRX)?
IMMUNITYBIO INC (IBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
What is the market capitalization of IBRX stock?
IMMUNITYBIO INC (IBRX) has a market capitalization of 2.01B USD. This makes IBRX a Mid Cap stock.
IBRX Technical Analysis
IBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IBRX. IBRX may be in some trouble as it scores bad on both profitability and health.
IBRX Financial Highlights
Over the last trailing twelve months IBRX reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 52.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.17% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IBRX Forecast & Estimates
11 analysts have analysed IBRX and the average price target is 10.61 USD. This implies a price increase of 420% is expected in the next year compared to the current price of 2.04.
For the next year, analysts expect an EPS growth of 24.42% and a revenue growth 639.35% for IBRX